This article reports on a conflict between the inventor of a medicine for dry eyes and the university where she worked, which highlights the pitfalls in commercialization of academic discoveries. Renee L. Kaswan, the former professor of veterinary medicine at the University of Georgia has been prodding the institution to be more aggressive in commercializing her invention for more than a decade. Although she and the university stand to make some $70-million from a license on the invention used for the popular eyedrops Restasis, sold by Allergan Inc., Dr. Kaswan contends that the university would be entitled to substantially more--as much as $230-million in additional cash--were it not for the deal its research foundation cut with Allergan behind her back in 2003, a deal she calls naive and shortsighted. The 2003 deal allowed Allergan to reduce the royalties it was obliged to pay to the university, in exchange for an upfront payment of $23-million and additional payments later. The dispute that is now slowly working its way through a state court in Georgia shows why so few university inventions become blockbusters for their institutions. The documents in the case highlight the difficulties inherent in university technology transfer when the interests of faculty members passionate about their inventions clash with the more cautious culture of the university ultimately responsible for the intellectual property.